Bayer's Roundup Cap Is Court-Approved, but the Payment Clock Still Hasn't Started
Published on 11/22/2026 at 02:51 | Editorial boerse-global.deBayer's US launch of SUNHARBO (asundexian) as an orderable 50-milligram tablet drew a modest market response on Friday, with the stock adding 1.2% to EUR 55.16. The product is now available to hospitals, health systems and pharmacies across the United States.
The same day brought a more consequential legal development: a Missouri court has granted final approval to Bayer's nationwide settlement of Roundup claims tied to non-Hodgkin lymphoma. Judge Timothy Boyer signed off on the deal, though the ruling is still subject to appeal and is not yet legally final.
What the Settlement Actually Commits
Under the agreement, Monsanto is to fund a compensation pool with annual payments spread over as many as 21 years. The installments are capped each year and are designed to decline over time, with total outlays limited to a maximum of USD 7.25 billion — a figure that includes sums already paid out. Because prior disbursements count against the ceiling, investors should focus on the annual limits that govern cash outflow rather than the headline total alone.
Timing is the open question. An appeal could suspend payments until the appellate process concludes, pushing the start of funding into uncertain territory. How many claimants ultimately join the settlement has also not been disclosed, leaving the deal's true reach dependent on how many affected parties choose to resolve their claims through the fund.
Should investors sell immediately? Or is it worth buying Bayer?
Who the Fund Covers — and Who It Doesn't
The settlement is structured to capture the bulk of pending and potential future US lawsuits over non-Hodgkin lymphoma. It also provides compensation for people diagnosed within 16 years of the agreement taking effect, provided they had contact with Roundup before February 17. Reuters puts the number of outstanding claims at roughly 65,000, while about 200 cases before federal courts fall outside the settlement's scope. Bayer makes no admission of liability, and the company continues to deny that Roundup causes cancer.
The backdrop is costly. Since acquiring Monsanto in 2018, Bayer has paid out around USD 10 billion in settlements, according to Deutschlandfunk. In June, the US Supreme Court also ruled that certain claims alleging a failure to warn about cancer risks on Roundup packaging are precluded. Beyond glyphosate, the company faces further litigation exposure, including PCB proceedings, as WirtschaftsWoche has noted.
Berenberg Raises Its Target
On the analyst side, Berenberg lifted its price target on Bayer on November 17 to EUR 62.00 from EUR 53.50, keeping its rating at "Hold." The revision landed alongside Bayer's third-quarter 2026 results, which showed group revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion. The company also adjusted its full-year guidance, including for EBITDA before special items, free cash flow and net financial debt.
Bayer at a turning point? This analysis reveals what investors need to know now.
CEO Bill Anderson has called the court's approval a decisive milestone in containing both active and potential future litigation. For now, the long-term payment framework is in place — what remains unresolved is whether an appeal materializes and, if it does, how far it delays the first inflows into the fund.
Ad
Bayer Stock: New Analysis - 22 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
